Remove 2020 Remove Labelling Remove Pharmaceutical Manufacturing
article thumbnail

Pharmacy Policy Updates for June 2025

Pharmacy Times

The first one was introduced on September 13, 2020, near the end of Trump’s first term, but was shut down by a federal judge due to the administration’s failure to comply with the proper implementation processes. September 13, 2020. Trump to pitch sweeping Medicare drug price plan. May 7, 2025. Accessed May 13, 2025.

article thumbnail

Common pharma compliance concerns cited by FDA warning letters

European Pharmaceutical Review

A study of the causes of warning letters issued by the US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) between 2010 and 2020 revealed that poor current good manufacturing practice (cGMP) compliance and misbranding were the most common citations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

At Agilent, we believe that sustainability, productivity and efficiency can co-exist in a lab without compromising on ROI

Express Pharma

At Agilent, sustainability is a top priority for our product development and manufacturing processes. In 2020, we began partnering with My Green Lab to advance our sustainability efforts. Initially, we began by partnering with My Green Lab on the organisation’s ACT Environmental Impact Factor Label programme.

article thumbnail

The Pandemic Treaty and the opportunity to end ‘vaccine apartheid’

pharmaphorum

The world was caught unprepared for the global pandemic that struck in 2020. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general. There are now efforts to ensure that the same is not allowed to happen again.

article thumbnail

NHC Submits Comments on FDA Draft Guidance on AI to Support Regulatory Decision-Making for Drugs/Biologics

Putting Patients First Blog

Furthermore, FDA guidance should include requirements for clear labeling and disclosure of any remaining performance limitations or biases, ensuring clinicians and patients are aware of potential constraints in real-world contexts.

article thumbnail

Deviation investigation guidelines in the pharmaceutical industry

GMPSOP

Adulterated Pharmaceuticals: 396 warnings iii. Packaging/labeling/Misbranding: 41 warnings vi. In 2019 and 2020, warning letters were issued for “Adulterated Food and Supplements” at 36% and 33%, respectively. Similarly, the packaging, labeling, and misbranding-related warning letters were the top reasons in 2019.

article thumbnail

What Does the “Most Favored Nation” Executive Order Mean for Personal Use Imports?

FDA Law Blog: Biosimilars

Wasserstein We are still parsing through the May 12 Executive Order (EO), Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients and impacts this may have on the pharmaceutical industry. Weve blogged about Most-Favored-Nation (MFN) drug pricing and how the new EO goes well beyond the 2020 order and questions we have.